Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 6

1.

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW.

Ann Oncol. 2008 Oct;19(10):1759-64. doi: 10.1093/annonc/mdn365. Epub 2008 May 25.

2.

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Leonard JP, Furman RR, Coleman M.

Int J Cancer. 2006 Sep 1;119(5):971-9. Review.

3.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
4.

Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Mato AR, Feldman T, Goy A.

Oncologist. 2012;17(5):694-707. doi: 10.1634/theoncologist.2011-0341. Epub 2012 May 7. Review.

5.

The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.

O'Connor OA.

Curr Treat Options Oncol. 2004 Aug;5(4):269-81. Review.

PMID:
15233904
6.

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

Oki Y, Younes A.

Leuk Lymphoma. 2008 May;49(5):883-9. doi: 10.1080/10428190801911704. Review.

PMID:
18452104
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk